{"pmid":32312892,"title":"Adapting to a pandemic - conducting oncology trials during the SARS-CoV-2 pandemic.","text":["Adapting to a pandemic - conducting oncology trials during the SARS-CoV-2 pandemic.","The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic has necessitated changes in cancer care delivery as resources are reallocated. Clinical trials and other research activities are inevitably impacted. Start-up activities for new trials may be deferred and recruitment suspended. For patients already enrolled however, there are challenges in continuing treatment on trial. Regulatory bodies have issued guidance on managing clinical trials during the pandemic, including contingency measures for remote study visits, delivery of investigational product and site monitoring visits. New cancer clinical trial practices during the SARS-CoV-2 pandemic include new risk assessment strategies, decentralized and remote trial co-ordination, data collection and delegation of specific therapeutic activities. This experience could provide evidence of more feasible and cost-effective methods for future clinical trial conduct.","Clin Cancer Res","Tan, Aaron C","Ashley, David M","Khasraw, Mustafa","32312892"],"abstract":["The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic has necessitated changes in cancer care delivery as resources are reallocated. Clinical trials and other research activities are inevitably impacted. Start-up activities for new trials may be deferred and recruitment suspended. For patients already enrolled however, there are challenges in continuing treatment on trial. Regulatory bodies have issued guidance on managing clinical trials during the pandemic, including contingency measures for remote study visits, delivery of investigational product and site monitoring visits. New cancer clinical trial practices during the SARS-CoV-2 pandemic include new risk assessment strategies, decentralized and remote trial co-ordination, data collection and delegation of specific therapeutic activities. This experience could provide evidence of more feasible and cost-effective methods for future clinical trial conduct."],"journal":"Clin Cancer Res","authors":["Tan, Aaron C","Ashley, David M","Khasraw, Mustafa"],"date":"2020-04-22T11:00:00Z","year":2020,"_id":"32312892","week":"202017|Apr 20 - Apr 26","doi":"10.1158/1078-0432.CCR-20-1364","source":"PubMed","topics":["Prevention"],"weight":1,"_version_":1664714520168235010,"score":8.518259,"similar":[{"pmid":32250281,"title":"Conducting Clinical Research During the COVID-19 Pandemic: Investigator and Participant Perspectives.","text":["Conducting Clinical Research During the COVID-19 Pandemic: Investigator and Participant Perspectives.","As the medical landscape changes daily with the coronavirus disease (COVID-19) pandemic, clinical researchers are caught off-guard and are forced to make decisions on research visits in their ongoing clinical trials. Although there is some guidance from local and national organizations, the principal investigator (PI) is ultimately responsible for determining the risk-benefit ratio of conducting, rescheduling, or cancelling each research visit. The PI should take into consideration the ethical principles of research, local/national guidance, the community risk of the pandemic in their locale, staffing strain, and the risk involved to each participant, to ultimately decide on the course of action. While balancing the rights and protection of the human subject, we seldom examine patients' views and opinions about their scheduled research visit(s). This article discusses the ethical principles of beneficence and autonomy in helping the decision-making process. We discuss ways to weigh-in local and national guidance, staffing strain, and institutional support into the decision-making process and outline potential changes needed for regulatory bodies depending on the decision. Further, we discuss the need to weigh-in the individual risk-benefit ratio for each participant and present a decision tree to navigate this complex process. Finally, we examine participant and caregiver perspectives on their fears, sense of preparedness, and factors that they consider before deciding whether to keep or postpone the research appointments. This entry also provides PIs ways to support their research participants in both scenarios, including provision of psychological support.","JMIR Public Health Surveill","Padala, Prasad R","Jendro, Ashlyn M","Padala, Kalpana P","32250281"],"abstract":["As the medical landscape changes daily with the coronavirus disease (COVID-19) pandemic, clinical researchers are caught off-guard and are forced to make decisions on research visits in their ongoing clinical trials. Although there is some guidance from local and national organizations, the principal investigator (PI) is ultimately responsible for determining the risk-benefit ratio of conducting, rescheduling, or cancelling each research visit. The PI should take into consideration the ethical principles of research, local/national guidance, the community risk of the pandemic in their locale, staffing strain, and the risk involved to each participant, to ultimately decide on the course of action. While balancing the rights and protection of the human subject, we seldom examine patients' views and opinions about their scheduled research visit(s). This article discusses the ethical principles of beneficence and autonomy in helping the decision-making process. We discuss ways to weigh-in local and national guidance, staffing strain, and institutional support into the decision-making process and outline potential changes needed for regulatory bodies depending on the decision. Further, we discuss the need to weigh-in the individual risk-benefit ratio for each participant and present a decision tree to navigate this complex process. Finally, we examine participant and caregiver perspectives on their fears, sense of preparedness, and factors that they consider before deciding whether to keep or postpone the research appointments. This entry also provides PIs ways to support their research participants in both scenarios, including provision of psychological support."],"journal":"JMIR Public Health Surveill","authors":["Padala, Prasad R","Jendro, Ashlyn M","Padala, Kalpana P"],"date":"2020-04-07T11:00:00Z","year":2020,"_id":"32250281","week":"202015|Apr 06 - Apr 12","doi":"10.2196/18887","keywords":["COVID-19","clinical research","ethics","infectious disease","outbreak","pandemic","public health"],"source":"PubMed","weight":0,"_version_":1663352136307572736,"score":196.57135},{"pmid":32319433,"title":"[CoViD-19: we knew everything but we didn't understand anything.]","text":["[CoViD-19: we knew everything but we didn't understand anything.]","The CoViD-19 and its consequences could perhaps have been foreseen. Above all, this pandemic force us to review what is essential and really necessary in term of priorities and regulatory process for clinical pharmacological research. It is evident, among other things, the difficulty to deal with therapeutic uncertainties.Not proven specific therapies are available for the SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2, the cause of CoViD-19), other than supportive care. However, several clinical centres decided to use off label drugs as a standard of care in the absence of efficacy and safety data. The national regulatory body (AIFA) has set up a process in a short time to transparently govern the approval of new trials and to regulate the use of medicines that are not indicated. In this context, the communication of risk associated with experimental therapies was also very important. The lessons we will learn from this emergency may result crucial in redesigning a better way of conducting clinical trials and information on drugs.","Recenti Prog Med","Addis, Antonio","32319433"],"abstract":["The CoViD-19 and its consequences could perhaps have been foreseen. Above all, this pandemic force us to review what is essential and really necessary in term of priorities and regulatory process for clinical pharmacological research. It is evident, among other things, the difficulty to deal with therapeutic uncertainties.Not proven specific therapies are available for the SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2, the cause of CoViD-19), other than supportive care. However, several clinical centres decided to use off label drugs as a standard of care in the absence of efficacy and safety data. The national regulatory body (AIFA) has set up a process in a short time to transparently govern the approval of new trials and to regulate the use of medicines that are not indicated. In this context, the communication of risk associated with experimental therapies was also very important. The lessons we will learn from this emergency may result crucial in redesigning a better way of conducting clinical trials and information on drugs."],"journal":"Recenti Prog Med","authors":["Addis, Antonio"],"date":"2020-04-23T11:00:00Z","year":2020,"_id":"32319433","week":"202017|Apr 20 - Apr 26","doi":"10.1701/3347.33174","source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1664815087736586240,"score":183.39122},{"pmid":32292826,"pmcid":"PMC7141164","title":"A living systematic review protocol for COVID-19 clinical trial registrations.","text":["A living systematic review protocol for COVID-19 clinical trial registrations.","Since the coronavirus disease 2019 (COVID-19) outbreak was identified in December 2019 in Wuhan, China, a strong response from the research community has been observed with the proliferation of independent clinical trials assessing diagnostic methods, therapeutic and prophylactic strategies. While there is no intervention for the prevention or treatment of COVID-19 with proven clinical efficacy to date, tools to distil the current research landscape by intervention, level of evidence and those studies likely powered to address future research questions is essential. This living systematic review aims to provide an open, accessible and frequently updated resource summarising the characteristics of COVID-19 clinical trial registrations. Weekly search updates of the WHO International Clinical Trials Registry Platform (ICTRP) and source registries will be conducted. Data extraction by two independent reviewers of trial characteristic variables including categorisation of trial design, geographic location, intervention type and targets, level of evidence and intervention adaptability to low resource settings will be completed. Descriptive and thematic synthesis will be conducted. A searchable and interactive visualisation of the results database will be created, and made openly available online. Weekly results from the continued search updates will be published and made available on the Infectious Diseases Data Observatory (IDDO) website ( COVID-19 website). This living systematic review will provide a useful resource of COVID-19 clinical trial registrations for researchers in a rapidly evolving context. In the future, this sustained review will allow prioritisation of research targets for individual patient data meta-analysis.","Wellcome Open Res","Maguire, Brittany J","Guerin, Philippe J","32292826"],"abstract":["Since the coronavirus disease 2019 (COVID-19) outbreak was identified in December 2019 in Wuhan, China, a strong response from the research community has been observed with the proliferation of independent clinical trials assessing diagnostic methods, therapeutic and prophylactic strategies. While there is no intervention for the prevention or treatment of COVID-19 with proven clinical efficacy to date, tools to distil the current research landscape by intervention, level of evidence and those studies likely powered to address future research questions is essential. This living systematic review aims to provide an open, accessible and frequently updated resource summarising the characteristics of COVID-19 clinical trial registrations. Weekly search updates of the WHO International Clinical Trials Registry Platform (ICTRP) and source registries will be conducted. Data extraction by two independent reviewers of trial characteristic variables including categorisation of trial design, geographic location, intervention type and targets, level of evidence and intervention adaptability to low resource settings will be completed. Descriptive and thematic synthesis will be conducted. A searchable and interactive visualisation of the results database will be created, and made openly available online. Weekly results from the continued search updates will be published and made available on the Infectious Diseases Data Observatory (IDDO) website ( COVID-19 website). This living systematic review will provide a useful resource of COVID-19 clinical trial registrations for researchers in a rapidly evolving context. In the future, this sustained review will allow prioritisation of research targets for individual patient data meta-analysis."],"journal":"Wellcome Open Res","authors":["Maguire, Brittany J","Guerin, Philippe J"],"date":"2020-04-16T11:00:00Z","year":2020,"_id":"32292826","week":"202016|Apr 13 - Apr 19","doi":"10.12688/wellcomeopenres.15821.1","keywords":["covid-19","living systematic review","clinical trials","coronavirus","emerging infections"],"source":"PubMed","topics":["Treatment"],"weight":1,"locations":["Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"_version_":1664636192696565761,"score":183.02048},{"pmid":32292626,"pmcid":"PMC7102592","title":"Core Outcome Set for Clinical Trials on Coronavirus Disease 2019 (COS-COVID).","text":["Core Outcome Set for Clinical Trials on Coronavirus Disease 2019 (COS-COVID).","Since its outbreak in December 2019, a series of clinical trials on Coronavirus Disease 2019 (COVID-19) have been registered or carried out. However, the significant heterogeneity and less critical outcomes of such trials may be leading to a waste of research resources. This study aimed to develop a core outcome set (COS) for clinical trials on COVID-19 in order to tackle the outcome issues. The study was conducted according to the Core Outcome Measures in Effectiveness Trials (COMET) handbook (version 1.0), a guideline for COS development. A research group was set up that included experts in respiratory and critical medicine, traditional Chinese medicine, evidence-based medicine, clinical pharmacology, and statistics, in addition to medical journal editors. Clinical trial registry websites (chictr.org.cn and clinicaltrials.gov) were searched to retrieve clinical trial protocols and outcomes in order to form an outcome pool. A total of 78 clinical trial protocols on COVID-19 were included and 259 outcomes were collected. After standardization, 132 outcomes were identified within seven different categories, of which 58 were selected to develop a preliminary outcome list for further consensus. After two rounds of Delphi survey and one consensus meeting, the most important outcomes for the different clinical classifications of COVID-19 were identified and determined to constitute the COS for clinical trials on COVID-19 (COS-COVID). The COS-COVID includes one outcome for the mild type (time to 2019-nCoV reverse transcription-polymerase chain reaction (RT-PCR) negativity), four outcomes for the ordinary type (length of hospital stay, composite events, score of clinical symptoms, and time to 2019-nCoV RT-PCR negativity), five outcomes for the severe type (composite events, length of hospital stay, arterial oxygen partial pressure (PaO2)/fraction of inspired oxygen (FiO2), duration of mechanical ventilation, and time to 2019-nCoV RT-PCR negativity), one outcome for critical type (all-cause mortality), and one outcome for rehabilitation period (pulmonary function). The COS-COVID is currently the most valuable and practical clinical outcome set for the evaluation of intervention effect, and is useful for evidence assessment and decision-making. With a deepening understanding of COVID-19 and application feedback, the COS-COVID should be continuously updated.","Engineering (Beijing)","Jin, Xinyao","Pang, Bo","Zhang, Junhua","Liu, Qingquan","Yang, Zhongqi","Feng, Jihong","Liu, Xuezheng","Zhang, Lei","Wang, Baohe","Huang, Yuhong","Josephine Fauci, Alice","Ma, Yuling","Soo Lee, Myeong","Yuan, Wei'an","Xie, Yanming","Tang, Jianyuan","Gao, Rui","Du, Liang","Zhang, Shuo","Qi, Hanmei","Sun, Yu","Zheng, Wenke","Yang, Fengwen","Chua, Huizi","Wang, Keyi","Ou, Yi","Huang, Ming","Zhu, Yan","Yu, Jiajie","Tian, Jinhui","Zhao, Min","Hu, Jingqing","Yao, Chen","Li, Youping","Zhang, Boli","32292626"],"abstract":["Since its outbreak in December 2019, a series of clinical trials on Coronavirus Disease 2019 (COVID-19) have been registered or carried out. However, the significant heterogeneity and less critical outcomes of such trials may be leading to a waste of research resources. This study aimed to develop a core outcome set (COS) for clinical trials on COVID-19 in order to tackle the outcome issues. The study was conducted according to the Core Outcome Measures in Effectiveness Trials (COMET) handbook (version 1.0), a guideline for COS development. A research group was set up that included experts in respiratory and critical medicine, traditional Chinese medicine, evidence-based medicine, clinical pharmacology, and statistics, in addition to medical journal editors. Clinical trial registry websites (chictr.org.cn and clinicaltrials.gov) were searched to retrieve clinical trial protocols and outcomes in order to form an outcome pool. A total of 78 clinical trial protocols on COVID-19 were included and 259 outcomes were collected. After standardization, 132 outcomes were identified within seven different categories, of which 58 were selected to develop a preliminary outcome list for further consensus. After two rounds of Delphi survey and one consensus meeting, the most important outcomes for the different clinical classifications of COVID-19 were identified and determined to constitute the COS for clinical trials on COVID-19 (COS-COVID). The COS-COVID includes one outcome for the mild type (time to 2019-nCoV reverse transcription-polymerase chain reaction (RT-PCR) negativity), four outcomes for the ordinary type (length of hospital stay, composite events, score of clinical symptoms, and time to 2019-nCoV RT-PCR negativity), five outcomes for the severe type (composite events, length of hospital stay, arterial oxygen partial pressure (PaO2)/fraction of inspired oxygen (FiO2), duration of mechanical ventilation, and time to 2019-nCoV RT-PCR negativity), one outcome for critical type (all-cause mortality), and one outcome for rehabilitation period (pulmonary function). The COS-COVID is currently the most valuable and practical clinical outcome set for the evaluation of intervention effect, and is useful for evidence assessment and decision-making. With a deepening understanding of COVID-19 and application feedback, the COS-COVID should be continuously updated."],"journal":"Engineering (Beijing)","authors":["Jin, Xinyao","Pang, Bo","Zhang, Junhua","Liu, Qingquan","Yang, Zhongqi","Feng, Jihong","Liu, Xuezheng","Zhang, Lei","Wang, Baohe","Huang, Yuhong","Josephine Fauci, Alice","Ma, Yuling","Soo Lee, Myeong","Yuan, Wei'an","Xie, Yanming","Tang, Jianyuan","Gao, Rui","Du, Liang","Zhang, Shuo","Qi, Hanmei","Sun, Yu","Zheng, Wenke","Yang, Fengwen","Chua, Huizi","Wang, Keyi","Ou, Yi","Huang, Ming","Zhu, Yan","Yu, Jiajie","Tian, Jinhui","Zhao, Min","Hu, Jingqing","Yao, Chen","Li, Youping","Zhang, Boli"],"date":"2020-04-16T11:00:00Z","year":2020,"_id":"32292626","week":"202016|Apr 13 - Apr 19","doi":"10.1016/j.eng.2020.03.002","keywords":["2019-ncov","covid-19","clinical trials","core outcome set","coronavirus disease"],"source":"PubMed","topics":["Treatment"],"weight":1,"locations":["Chinese"],"countries":["China"],"countries_codes":["CHN|China"],"_version_":1664636192629456896,"score":181.09985},{"pmid":32267771,"title":"The Randomized Embedded Multifactorial Adaptive Platform for Community-acquired Pneumonia (REMAP-CAP) Study: Rationale and Design.","text":["The Randomized Embedded Multifactorial Adaptive Platform for Community-acquired Pneumonia (REMAP-CAP) Study: Rationale and Design.","There is broad interest in improved methods to generate robust evidence regarding best practice, especially in settings where patient conditions are heterogenous and require multiple concomitant therapies. Here, we present the rationale and design of a large, international trial that combines features of adaptive platform trials with pragmatic point-of-care trials to determine best treatment strategies for patients admitted to an intensive care unit with severe community-acquired pneumonia (CAP). The trial uses a novel design entitled a randomized embedded multifactorial adaptive platform (REMAP). The design has 5 key features: i.) randomization, allowing robust causal inference; ii.) embedding of study procedures into routine care processes, facilitating enrollment, trial efficiency, and generalizability; iii.) a multifactorial statistical model comparing multiple interventions across multiple patient subgroups; iv.) response-adaptive randomization with preferential assignment to those interventions that appear most favorable, and v.) a platform structured to permit continuous, potentially perpetual enrollment beyond the evaluation of the initial treatments. The trial randomizes patients to multiple interventions within 4 treatment domains: antibiotics, antiviral therapy for influenza, host immunomodulation with extended macrolide therapy, and alternative corticosteroid regimens, representing 240 treatment regimens. The trial generates estimates of superiority, inferiority and equivalence between regimens on the primary outcome of 90-day mortality, stratified by presence or absence of concomitant shock and proven or suspected influenza infection. The trial will also compare ventilatory and oxygenation strategies and has capacity to address additional questions rapidly during pandemic respiratory infections. As of January 2020, REMAP-CAP was approved and enrolling patients in 52 ICUs in 13 countries in 3 continents. In February, it transitioned into pandemic mode with several design adaptations for COVID-19 disease. Lessons learned from the design and conduct of this trial should aid in dissemination of similar platform initiatives in other disease areas. Clinical trial registered with ClinicalTrials.gov (NCT02735707).","Ann Am Thorac Soc","Angus, Derek C","Berry, Scott","Lewis, Roger J","Al-Beidh, Farah","Arabi, Yaseen","van Bentum-Puijk, Wilma","Bhimani, Zahra","Bonten, Marc","Broglio, Kristine","Brunkhorst, Frank","Cheng, Allen C","Chiche, Jean-Daniel","De Jong, Menno","Detry, Michelle","Goossens, Herman","Gordon, Anthony","Green, Cameron","Higgins, Alisa M","Hullegie, Sebastiaan J","Kruger, Peter","Lamontagne, Francois","Litton, Edward","Marshall, John","McGlothlin, Anna","McGuinness, Shay","Mouncey, Paul","Murthy, Srinivas","Nichol, Alistair","O'Neill, Genevieve K","Parke, Rachael","Parker, Jane","Rohde, Gernot","Rowan, Kathryn","Turner, Anne","Young, Paul","Derde, Lennie","McArthur, Colin","Webb, Steven A","32267771"],"abstract":["There is broad interest in improved methods to generate robust evidence regarding best practice, especially in settings where patient conditions are heterogenous and require multiple concomitant therapies. Here, we present the rationale and design of a large, international trial that combines features of adaptive platform trials with pragmatic point-of-care trials to determine best treatment strategies for patients admitted to an intensive care unit with severe community-acquired pneumonia (CAP). The trial uses a novel design entitled a randomized embedded multifactorial adaptive platform (REMAP). The design has 5 key features: i.) randomization, allowing robust causal inference; ii.) embedding of study procedures into routine care processes, facilitating enrollment, trial efficiency, and generalizability; iii.) a multifactorial statistical model comparing multiple interventions across multiple patient subgroups; iv.) response-adaptive randomization with preferential assignment to those interventions that appear most favorable, and v.) a platform structured to permit continuous, potentially perpetual enrollment beyond the evaluation of the initial treatments. The trial randomizes patients to multiple interventions within 4 treatment domains: antibiotics, antiviral therapy for influenza, host immunomodulation with extended macrolide therapy, and alternative corticosteroid regimens, representing 240 treatment regimens. The trial generates estimates of superiority, inferiority and equivalence between regimens on the primary outcome of 90-day mortality, stratified by presence or absence of concomitant shock and proven or suspected influenza infection. The trial will also compare ventilatory and oxygenation strategies and has capacity to address additional questions rapidly during pandemic respiratory infections. As of January 2020, REMAP-CAP was approved and enrolling patients in 52 ICUs in 13 countries in 3 continents. In February, it transitioned into pandemic mode with several design adaptations for COVID-19 disease. Lessons learned from the design and conduct of this trial should aid in dissemination of similar platform initiatives in other disease areas. Clinical trial registered with ClinicalTrials.gov (NCT02735707)."],"journal":"Ann Am Thorac Soc","authors":["Angus, Derek C","Berry, Scott","Lewis, Roger J","Al-Beidh, Farah","Arabi, Yaseen","van Bentum-Puijk, Wilma","Bhimani, Zahra","Bonten, Marc","Broglio, Kristine","Brunkhorst, Frank","Cheng, Allen C","Chiche, Jean-Daniel","De Jong, Menno","Detry, Michelle","Goossens, Herman","Gordon, Anthony","Green, Cameron","Higgins, Alisa M","Hullegie, Sebastiaan J","Kruger, Peter","Lamontagne, Francois","Litton, Edward","Marshall, John","McGlothlin, Anna","McGuinness, Shay","Mouncey, Paul","Murthy, Srinivas","Nichol, Alistair","O'Neill, Genevieve K","Parke, Rachael","Parker, Jane","Rohde, Gernot","Rowan, Kathryn","Turner, Anne","Young, Paul","Derde, Lennie","McArthur, Colin","Webb, Steven A"],"date":"2020-04-09T11:00:00Z","year":2020,"_id":"32267771","week":"202015|Apr 06 - Apr 12","doi":"10.1513/AnnalsATS.202003-192SD","source":"PubMed","topics":["Treatment"],"weight":1,"locations":["iii.","Pneumonia"],"e_drugs":["Macrolides"],"_version_":1664637636108615680,"score":177.2289}]}